TargetBeta
SLC10A1
solute carrier family 10 member 1 · also NTCP, NTCP1 · Solute carrier family 10
2 programs in company-led studies act on SLC10A1, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| hepalatiderule | Shanghai HEP Pharmaceutical | phase 3 | 81 running | – | ChEMBL |
| bulevirtiderule | Gilead Sciences | phase 3 | 51 running | – | ChEMBL |
Conditions their studies are in
- Hepatitis D, Chronic, 2 programs
- Diabetes Mellitus, Type 2, 1 program
- Hepatitis B, Chronic, 1 program
- Hepatitis D, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 31, 2027bulevirtide · Gilead Sciences · phase 3 · NCT07454837
- Jun 2028hepalatide · Shanghai HEP Pharmaceutical · phase 3 · NCT07309380
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.